Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 24,867 shares of PLX stock, worth $60,675. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,867
Previous 36,438
31.76%
Holding current value
$60,675
Previous $37,000
27.03%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
4.58MCall Options Held
40.9KPut Options Held
5.3K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.12MShares$2.73 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL732KShares$1.79 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$946,5270.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$812,9370.0% of portfolio
-
Gsa Capital Partners LLP London, X0306KShares$746,0270.04% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $121M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...